A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus

EdiGene

Status and phase

Not yet enrolling

Phase 1

Conditions

Lupus Erythematosus, Systemic

Treatments

Drug: Cyclophosphamide

Drug: Fludarabine

Biological: ATHENA CAR-T

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT06373991

EDI-901-SLE01

Details and patient eligibility

About

The goal of this clinical trial is to test ATHENA CAR-T injection in adults with moderate to severe Systemic Lupus Erythematosus. The main question it aims to answer is:

• To evaluate the safety and tolerability of ATHENA CAR-T.

After screening, participants will be subjected to lymphodepletion regimen. After recovery, participants will be injected with ATHENA CAR-T injection and followed up to 24 months.

Full description

This study is a single center, one-arm, open label, phase I study aimed at evaluate the safety and effectiveness of ATHENA CAR-T treating moderate to severe SLE patients.

A traditional "3+3" design is used with two doses. DLT is monitored. Safety and effectiveness are followed up until 24 months post infusion of ATHENA CAR-T. Besides safety monitoring, efficacy is evaluated via SLEDAI-2000, BILAG-2004, PGA.

Enrollment

12 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or Female, between 18 and 56 years old;
diagnosed with SLE according to 2019 EULAR/ACR SLE classifications;
anti-Nuclear Antigen Ab positive (titer NLT 1:80) and/or dsDNA ab positive and/or Anti-Sm ab positive at screening;
at screening, SLEDAI-2000 scoring NLT 8 points, if low complement scoring and/or anti-dsDNA ab scoring is available, the SLEDAI-2000 scoring except low complement and anti-dsDNA ab should be NLT 6 points;
should be subjected to at least 6 months of standard treatment for SLE, and disease active at least two months before screening;
good organ functions;
trial participants whose partner is fertile agree to use effective contraceptives til 24 months post transfusion, fertile female participants should have negative urine/blood pregnancy test results (participants who were sterilized or menopause for MT 12 months is not considered fertile);
voluntary participates this trial and can comprehend and sign ICF.

Exclusion criteria

Had or has active malignancy;
had been subjected to treatment by CD19 targeted therapy or CAR-T therapy or any gene therapy;
within 8 weeks before screening, had CNS disease caused by SLE or non-SLE diseases;
within 8 weeks before screening, had lupus crisis;
has following kidney diseases: within 8 weeks before randomization, had SLE with serious kidney involvement or need treatment using medications prohibited by protocol to treat active nephritis, or need hemodialysis or need treatment by prednisone MT 100mg/d for longer than 14d or equivalent therapy;
had serious allergy to any lymphodepletion medication or ingredients of ATHENA CAR-T;
has uncontrolled fungi, bacterial or viral infection or other infections investigator deemed not suitable to participate in the study;
combined with other autoimmune disease that needs treatment;
pregnant or lactating women;
has other factors that deemed not suitable by investigator.